Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Apellis Pharmaceuticals Inc
(NQ:
APLS
)
42.75
+1.05 (+2.52%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Apellis Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
Next >
APELLIS PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
August 04, 2023
From
Bernstein Liebhard LLP
Via
GlobeNewswire
APELLIS PHARMACEUTICALS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Apellis Pharmaceuticals, Inc. - APLS
August 03, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
Shareholder Alert: Robbins LLP Informs Shareholders of Class Action Filed Against Apellis Pharmaceuticals, Inc. (APLS)
August 03, 2023
From
Robbins LLP
Via
Business Wire
Apellis Pharmaceuticals Inc. (NASDAQ: APLS) is a Stock Spotlight on 5/25
May 25, 2023
Via
Investor Brand Network
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - APLS
August 03, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
APLS Investor Alert: Kessler Topaz Meltzer & Check, LLP and Bernstein Litowitz Berger & Grossmann LLP Announce the Filing of a Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc.
August 02, 2023
From
Kessler Topaz Meltzer & Check, LLP
Via
Business Wire
Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results
July 31, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 30 Months in Patients with Geographic Atrophy (GA)
July 30, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Provides Update on Review of Rare Safety Events with SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy
July 29, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals to Host Conference Call on July 31, 2023, to Discuss Second Quarter 2023 Financial Results
July 24, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
APLS Investigation Alert: Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claims on Behalf of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) Investors
July 21, 2023
From
Kessler Topaz Meltzer & Check, LLP
Via
Business Wire
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – APLS
July 18, 2023
From
The Rosen Law Firm, P.A.
Via
Business Wire
Apellis Announces Seven Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
July 10, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 06, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
June 07, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 06, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Reports Top-Line Results from Phase 2 MERIDIAN Study in ALS
May 25, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Are Small Caps a Harbinger of Market Declines?
May 09, 2023
The iShares Russell 2000 ETF outperformed the S&P 500 last week, but that may be short-lived. Small-cap momentum is often a bellwether for broad-market action.
Via
MarketBeat
Topics
ETFs
Stocks
Exposures
US Equities
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 05, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals Reports First Quarter 2023 Financial Results
May 04, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals to Present at the Bank of America Securities 2023 Healthcare Conference
May 03, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals to Host Conference Call on May 4, 2023, to Discuss First Quarter 2023 Financial Results
April 27, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Presents Phase 3 Functional Analyses of SYFOVRE™ (pegcetacoplan injection) for Geographic Atrophy
April 23, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Announces Validation of Four Marketing Applications for Pegcetacoplan for Geographic Atrophy
April 21, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Partners with Acclaimed Actor Henry Winkler to Raise Awareness of Geographic Atrophy (GA) for the GA Won’t Wait™ Campaign
April 17, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 06, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals Inc. (NASDAQ: APLS) Making Surprising Moves in Monday Session
April 03, 2023
Via
Investor Brand Network
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 06, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
March 01, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Option to Purchase Additional Shares
February 27, 2023
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.